New combo pill for high blood pressure enters first human tests
NCT ID NCT07421414
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial will test a new combination pill containing two blood pressure medicines (fimasartan and indapamide) in 48 healthy adults. The study compares the combined pill to taking each drug separately, measuring how the body absorbs the drugs and checking for side effects. It is a Phase 1 study, so it focuses on safety and drug levels, not on treating high blood pressure yet.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Fimasartan and Indapamide (a combination pill)
- What this could lead to
- If successful, this could lead to a simpler once-daily pill for high blood pressure, potentially improving patient adherence.
- What could go wrong
- This is a very early Phase 1 study in healthy volunteers, not patients. It only checks drug levels and safety, not whether the combo actually controls blood pressure. Many early-stage drugs fail to show benefit later.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESSENTIAL HYPERTENSION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a heart drug be a new key to controlling high blood pressure?
- A simple arm cuff may lower blood pressure without drugs
- AI tailors blood pressure drugs, outsmarting One-Size-Fits-All medicine
- Herbal capsule aims to tackle both high blood pressure and poor sleep
- New drug combo aims to tame stubborn high blood pressure
- New combo pill aims to tame stubborn high blood pressure